United BioSource Selects Oracle Cloud Safety Technology for its Safety Programs
United BioSource (UBC) has migrated its safety functions from on-premises to Oracle Argus Cloud Service, a safety case management solution.
Running on the security and performance of Oracle Cloud Infrastructure, Oracle Argus Cloud Service will provide UBC with safety case processing for its clinical trials as well as post-marketing programs. With it, UBC can optimize its workflow by automating routine steps, reducing manual work, and cutting processing times. It also enables UBC to address its global compliance goals with aggregated and expedited reporting.
Oracle Argus Cloud Service can provide UBC with safety case management features and benefits including:
- Capabilities to help address compliance with global regulations and standards
- Lower cost and complexity through SaaS deployment
- Efficient case processing via automation
- Analytics and reports
- Lower total cost of ownership
Reference
United BioSource, LLC Selects Oracle Cloud Safety Technology for its Safety Programs. (2023, August 1). Cision PR Newswire.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
